Projektdetaljer
Beskrivelse
Background: Compared with the general population, people with schizophrenia have a 2- to 3-fold higher mortality rate primarily caused by cardiovascular disease. Up to 20% of people with schizophrenia develop type 2 diabetes.
Objectives: To investigate the effects of the glucagon-like peptide-1 receptor agonist Semaglutide added to antipsychotic treatment of schizophrenia spectrum disorders.
Method: A randomized, placebo-controlled, double-blinded trial at two clinical sites in Denmark with 154 participants. Participants received stable treatment with 2. generation antipsychotics, were overweight or obese and had prediabetes. Main outcome is HbA1c. Secondary outcomes included psychotic symptoms, quality of life, BMI, and cardiometabolic parameters.
Funding:
Novo Nordisk Foundation
Steno Diabetes Center Sjaelland
Slagelsepuljen
Region Sjællands Sundhedsvidenskabelige Forskningsfond
Objectives: To investigate the effects of the glucagon-like peptide-1 receptor agonist Semaglutide added to antipsychotic treatment of schizophrenia spectrum disorders.
Method: A randomized, placebo-controlled, double-blinded trial at two clinical sites in Denmark with 154 participants. Participants received stable treatment with 2. generation antipsychotics, were overweight or obese and had prediabetes. Main outcome is HbA1c. Secondary outcomes included psychotic symptoms, quality of life, BMI, and cardiometabolic parameters.
Funding:
Novo Nordisk Foundation
Steno Diabetes Center Sjaelland
Slagelsepuljen
Region Sjællands Sundhedsvidenskabelige Forskningsfond
| Akronym | HISTORI |
|---|---|
| Status | Igangværende |
| Effektiv start/slut dato | 1/08/20 → 31/12/24 |